ECSP066999A - Envase farmacéutico para anticoncepción hormonal de régimen extendido flexible - Google Patents

Envase farmacéutico para anticoncepción hormonal de régimen extendido flexible

Info

Publication number
ECSP066999A
ECSP066999A EC2006006999A ECSP066999A ECSP066999A EC SP066999 A ECSP066999 A EC SP066999A EC 2006006999 A EC2006006999 A EC 2006006999A EC SP066999 A ECSP066999 A EC SP066999A EC SP066999 A ECSP066999 A EC SP066999A
Authority
EC
Ecuador
Prior art keywords
conception
pharmaceutical packaging
hormonal
flexible extended
hormonal anti
Prior art date
Application number
EC2006006999A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Sachse
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066999(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP066999A publication Critical patent/ECSP066999A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
EC2006006999A 2004-04-30 2006-11-13 Envase farmacéutico para anticoncepción hormonal de régimen extendido flexible ECSP066999A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
ECSP066999A true ECSP066999A (es) 2006-12-29

Family

ID=35056905

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006999A ECSP066999A (es) 2004-04-30 2006-11-13 Envase farmacéutico para anticoncepción hormonal de régimen extendido flexible

Country Status (29)

Country Link
US (3) US8163721B2 (https=)
EP (1) EP1747001B1 (https=)
JP (4) JP2007535519A (https=)
KR (4) KR20130022425A (https=)
CN (1) CN103127156A (https=)
AR (1) AR048722A1 (https=)
AU (1) AU2005237255B2 (https=)
BR (1) BRPI0510493A (https=)
CA (1) CA2562296A1 (https=)
CR (1) CR8709A (https=)
DK (1) DK1747001T3 (https=)
EA (2) EA016625B1 (https=)
EC (1) ECSP066999A (https=)
ES (1) ES2704999T3 (https=)
HU (1) HUE041475T2 (https=)
IL (1) IL178458A (https=)
LT (1) LT1747001T (https=)
MX (1) MXPA06012567A (https=)
MY (1) MY151322A (https=)
NO (1) NO341685B1 (https=)
NZ (1) NZ586107A (https=)
PA (1) PA8631801A1 (https=)
PE (1) PE20060467A1 (https=)
SG (2) SG10201701904TA (https=)
SI (1) SI1747001T1 (https=)
SV (1) SV2006002100A (https=)
TW (1) TWI374735B (https=)
UY (1) UY28875A1 (https=)
WO (1) WO2005105103A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11793812B2 (en) 2016-09-30 2023-10-24 Sumitomo Pharma Switzerland Gmbh Methods of treating endometriosis
US12551447B2 (en) 2020-05-29 2026-02-17 Sumitomo Pharma Co., Ltd. Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
JP2012502988A (ja) * 2008-09-16 2012-02-02 プレイテックス プロダクツ エルエルシー 月経抑制、避妊、およびホルモン補充療法のための製剤、ならびにその投与方法
CA2740004A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
ES2734510T3 (es) 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
US9198919B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
RS65196B1 (sr) * 2015-06-23 2024-03-29 Laboratorios Leon Farma Sa Kontraceptivno sredstvo na bazi drospirenona za pacijentkinje sa viškom težine
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
US12138270B2 (en) 2021-09-07 2024-11-12 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
AU3473193A (en) 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
DE69729956T2 (de) 1996-07-26 2004-12-16 Wyeth Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
JP4354667B2 (ja) 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11793812B2 (en) 2016-09-30 2023-10-24 Sumitomo Pharma Switzerland Gmbh Methods of treating endometriosis
US11957684B2 (en) 2016-09-30 2024-04-16 Sumitomo Pharma Switzerland Gmbh Treatment of heavy menstrual bleeding associated with uterine fibroids
US12551447B2 (en) 2020-05-29 2026-02-17 Sumitomo Pharma Co., Ltd. Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists

Also Published As

Publication number Publication date
EA031227B1 (ru) 2018-12-28
AR048722A1 (es) 2006-05-17
KR20150058555A (ko) 2015-05-28
WO2005105103A3 (en) 2006-09-08
JP6153967B2 (ja) 2017-06-28
US20150174142A1 (en) 2015-06-25
PE20060467A1 (es) 2006-06-11
AU2005237255B2 (en) 2011-07-07
IL178458A (en) 2016-08-31
LT1747001T (lt) 2019-01-25
NO341685B1 (no) 2017-12-18
JP2013018787A (ja) 2013-01-31
AU2005237255A1 (en) 2005-11-10
PA8631801A1 (es) 2006-11-09
SI1747001T1 (sl) 2019-02-28
SG10201701904TA (en) 2017-05-30
CR8709A (es) 2007-08-28
TW200603781A (en) 2006-02-01
JP2007535519A (ja) 2007-12-06
SG152288A1 (en) 2009-05-29
SV2006002100A (es) 2006-02-15
CN103127156A (zh) 2013-06-05
NO20065499L (no) 2006-11-29
KR20160150113A (ko) 2016-12-28
KR20070004919A (ko) 2007-01-09
HUE041475T2 (hu) 2019-05-28
MXPA06012567A (es) 2006-12-15
KR20130022425A (ko) 2013-03-06
TWI374735B (en) 2012-10-21
DK1747001T3 (en) 2019-02-04
EA200601908A1 (ru) 2007-04-27
EA201200377A1 (ru) 2012-08-30
KR101812160B1 (ko) 2017-12-27
EA016625B1 (ru) 2012-06-29
JP6134491B2 (ja) 2017-05-24
JP2015187157A (ja) 2015-10-29
IL178458A0 (en) 2008-04-13
EA201200377A8 (ru) 2018-01-31
US20120202779A1 (en) 2012-08-09
US20050250747A1 (en) 2005-11-10
UY28875A1 (es) 2005-11-30
US8163721B2 (en) 2012-04-24
EP1747001A2 (en) 2007-01-31
WO2005105103A2 (en) 2005-11-10
JP2017048253A (ja) 2017-03-09
NZ586107A (en) 2012-05-25
CA2562296A1 (en) 2005-11-10
EP1747001B1 (en) 2018-10-10
BRPI0510493A (pt) 2007-11-13
MY151322A (en) 2014-05-15
ES2704999T3 (es) 2019-03-21

Similar Documents

Publication Publication Date Title
ECSP066999A (es) Envase farmacéutico para anticoncepción hormonal de régimen extendido flexible
CY1120879T1 (el) Πολλαπλου συστατικου βιοδραστικος ενδοκολπικος δακτυλιος
BRPI0501449A (pt) Mistura funcional, processos para curar e para curar parcialmente uma mistura funcional, e, adesivo
AR061958A1 (es) Composicion farmaceutica que contiene un acido tetrahidrofolico
ECSP088097A (es) Nuevos regímenes para dispositivos de administración controlada de fármacos para anticoncepción
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
CO6241131A2 (es) Vacuna
CL2012002722A1 (es) Forma farmaceutica parenteral que libera un inhibidor de aromatasa tal como anastrozol y exemestano, y un gestageno tal como levonorgestrel y gestodeno; y su uso para el tratamiento simultaneo de endometriosis y para la anticoncepcion.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
BRPI0501450A (pt) Composição funcional, e, artigo
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CL2007001961A1 (es) Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.
HN2003000183A (es) Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
UY27894A1 (es) Derivados de cinamida.
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
CL2021003410A1 (es) Sistema para proporcionar control de la natalidad
MX2023001301A (es) Uso antiviral de liraglutida y gefitinib.
CL2008000999A1 (es) Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres.
GT200500268A (es) Inhibidores de la adenilato ciclasa soluble
CU20060204A7 (es) Tratamiento de la hemorragia de disrupción en regímenes anticonceptivos extendidos
BRPI0518172A (pt) prevenção de infecções verticais com endoparasitas